Recent Analysts’ Ratings Changes for Integer (ITGR)

Several analysts have recently updated their ratings and price targets for Integer (NYSE: ITGR):

• 7/24/2026 – Integer had its “buy” rating reaffirmed by HC Wainwright.
• 7/22/2026 – Integer was upgraded by Freedom Capital to “strong-buy”.
• 7/21/2026 – Integer had its “overweight” rating reaffirmed by KeyCorp. They now have a $104.00 price target on the stock.
• 7/20/2026 – Integer was upgraded by Zacks Research from “strong sell” to “hold”.
• 7/16/2026 – Integer had its price target raised by Truist Financial Corporation from $97.00 to $110.00. They now have a “buy” rating on the stock.
• 7/8/2026 – Integer had its price target raised by Citigroup Inc. from $92.00 to $96.00. They now have a “neutral” rating on the stock.
• 6/18/2026 – Integer had its “hold (c)” rating reaffirmed by Weiss Ratings.

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.